Home / Intelligence / Case Studies / Early Payer Guidance Across Four Inflammatory Disease Areas
Trinity completed an early payer guidance engagement, conducting comprehensive secondary research across four inflammatory disease areas.
Geographic Scope: 
Client Situation
The client wanted to gain an in-depth understanding of four inflammatory disease areas to inform early stage decision-making.
Trinity’s Solution
Trinity conducted comprehensive secondary research in the following areas:
- Disease background including diagnosis, prognosis, epidemiology and unmet needs
- Current and future paradigm including lines of therapies and standard of care
- Pipeline analysis including key therapies in development and future treatment gamechangers
- Pricing and access landscape including pricing analysis, health technology assessment (HTA) outcomes and access status
Deliverables
Four disease-specific early payer guidance reports powered by comprehensive secondary research efforts into disease background, current and future treatment paradigm, pipeline analysis and pricing and access landscape.
Project Outcomes & Impact
Trinity’s comprehensive secondary research and landscape analyses helped the client to make early-stage decisions across therapeutic areas of interest from a future business development perspective.
Related Intelligence
Webinars
2023 NRDL Update: An Ongoing Voyage of Innovation and Accessibility
May 1, 2024 | 12:00 – 12:45 PM ET / 18:00 – 18:45 CET
An additional session will be offered on May 7th at 16:00-16:45 (UTC+8:00) – Asia/Shanghai How can manufacturers strategize for pricing and market access success amidst the evolving landscape of China’s NRDL? As China continues to be a key pharmaceutical market, understanding the latest National Reimbursement Drug List (NRDL) trends and policy evolvement is crucial for […]
Sign Up Now
Blog
Rise with the waves: Canada – A Coming (R)evolution: Transforming Pharmaceutical Market Access
Executive Summary Canada has undertaken meaningful strategies to transform patient access and ultimately improve health outcomes across the country. Two such potentially high-impact strategies include the planned transformation of the former Canadian Agency for Drugs and Technology in Health (CADTH) into the new Canadian Drug Agency (CDA) over the course of the next five years, […]
Read More
Blog
Using Transparency in Coverage Reimbursement Insights to Inform Payer and Provider Contracting Strategy
Executive Summary “Transparency in Coverage” (TIC) data is a newer data source that has recently become available for mining unique insights in the reimbursement/economics between payers and providers. In 2020, the Federal Government TIC Rule required health insurers and group health plans, including self-funded clients, to provide cost-sharing data to consumers via machine-readable files and […]
Read More